1

1. appearance. Its gene resides over the longer arm of chromosome 19, encodes a protease of molecular mass 35 kDa, and it is from the external surface from the plasma membrane with a glycosyl-phosphatidylinositol anchor. When uPAR interacts with among its ligands, uPA, plasminogen is normally cleaved to energetic plasmin, which degrades many extracellular matrix (ECM) components and activates many promatrix metalloproteases also. As the ECM may be the main physical obstacle for cancers cells to penetrate and invade the encompassing tissues, proteolytic degradation from the ECM (-)-DHMEQ facilitates migration and penetration through tissues boundaries, resulting in metastasis. In addition, other signalling pathways are activated to induce cellular proliferation, motility, and additional remodelling of the ECM. Therefore, it is important to develop new targeting drugs to inhibit the activation of uPAR by uPA or any other ligand [1,2,3,4,5,6,7,8,9]. The other gene, the HER2 proto-oncogene, is usually amplified in 25% of invasive breast cancers, resulting in a decreased time of disease-free survival and other markers of poor prognosis. Trastuzumab (Herceptin; Genentech, South San Francisco, CA, USA) is usually a HER2-directed humanised antibody that is effective for the treatment of patients with metastatic or early-stage breast cancer [10,11,12]. The methods used for selecting patients for trastuzumab therapy are immunohistochemical (IHC) analysis and gene-based fluorescent in situ hybridisation (FISH) analysis of primary tumours. Retrospective studies have shown that measurement of gene amplification is the best predictive marker of response to trastuzumab-based therapy [13,14,15]. Here, we have analysed the uPAR and HER2 gene status in individual TCs from touch preps (TPs) of primary breast carcinomas and also from circulating TCs (CTCs) in patients with advanced recurrent breast carcinoma. One objective was to determine whether the uPAR gene, like HER2, can be (-)-DHMEQ amplified. A second objective was to determine the cellular distribution of the two amplified genes, e.g. whether they are amplified in individual TCs. Finally, we wanted to demonstrate the additional information that can be obtained from individual TC analysis. == Patients and Methods == == Patient Selection == Women with a documented histological diagnosis of primary breast carcinoma (-)-DHMEQ or those with advanced metastatic breast carcinoma and normal age-matched controls were recruited. All specimens were obtained with informed consent and collected using protocols approved by the Institutional Review Board at the University of Texas Southwestern Medical Center. == Tissue Acquisition Gfap == The University of Texas Southwestern Tissue Repository is usually a core facility that provided frozen breast cancer tissue from which we made TPs of primary cancers. Tumour tissue was washed for 2 min two times in 1-PBS and was cut (-)-DHMEQ into four sections. Each section was then touched gently onto a poly(l-lysine)-coated slide. Slides were air dried and fixed with 95% ethanol for 10 min. == Collection of Blood Samples == Of blood, 30 ml was drawn from the antecubital vein of patients into 10-ml Vacutainer tubes (BD Biosciences, San Diego, CA, USA), and CCTCs were isolated as previously described using an immunomagnetic assay [16]. == Antibodies == We used the following antibodies for direct staining: (i) fluorescein isoth-iocyanate (FITC)-labelled pan-anti-cytokeratin clone C11 (Sigma, St. Louis, MO, USA), (ii) anti-CD45 (clone 9.4 from American Type Culture Collection) conjugated in our laboratory to AlexaFluor 546 (Molecular Probes, Eugene, OR, USA), (iii) anti-HER81 mouse monoclonal antibody (E. Vitetta) conjugated to AlexaFluor 594, and (iv) anti-uPAR mouse monoclonal antibody, clone 62022 (R&D Systems, Minneapolis, MN, USA) conjugated in our laboratory to AlexaFluor 546. == Immunofluorescence Staining and Detection of CTCs == The detection of epithelial cells is usually accomplished by immunofluorescence (IF) using anti-CK and anti-CD45, as previously described [16]. Slides were examined manually for the presence of epithelial cells using a fluorescent microscope (Axiophot; Zeiss, Jena, Germany). Scanning for CK_and CD45_positive cells was performed with a single bandpass filter for FITC and AlexaFluor 546. To assure that this FITC staining was associated with the correct cell, the same area was evaluated with a dual bandpass filter for FITC-DAPI (DAPI: 4,6-diamidino-2-phenylindole dihy-drochloride). The location of each TC around the slide was recorded and stored. An image from each positive cell was acquired to confirm that this same cell was relocated.